bullish

Advanced Enzyme Technologies

Advanced Enzyme Technologies - Near Term Challenges Continue

ADVENZY’s 4QFY22 EBITDA came in ~19% below our estimate on account of decline in the Human Nutrition business, RM inflation and increase in other expenses.

Equity Bottom-Up
186 Views, 25 May 2022 08:11
SUMMARY(Sign Up to Access)
or
Full Insight
(Paid Plans Only)
Discussions
(Paid Plans Only)
WHAT’S TRENDING
Insights
  • Trending
  • Latest
Logo
Nirmal Bang
A Relationship Beyond Broking
IndiaEquity Bottom-UpThematic (Sector/Industry)

Nirmal Bang, one of the leading stock broking companies in India, caters to retail and institutional clients by offering... 

Price Chart(Sign Up to Access)
analytics-chart
x